We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Read MoreHide Full Article
Key Takeaways
Prime Medicine advances two investigational gene-editing therapies targeting the causes of genetic diseases.
FDA clearance allows PM647 to advance into U.S. clinical testing for alpha-1 antitrypsin deficiency.
PM577a begins phase I/II testing for Wilson disease, while PM577 receives Rare Pediatric Disease designation.
Prime Medicine (PRME - Free Report) shares have gained approximately 26% over the past month against the industry’s 2.8% decline, supported by encouraging clinical and regulatory progress across its gene-editing pipeline. Prime Medicine received FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency (AATD). The company also announced the dosing of the first patient in the phase I/II study of investigational PM577a for Wilson disease. These milestones highlight the potential of the company's Prime Editing platform to develop treatments that target the underlying causes of genetic diseases.
Image Source: Zacks Investment Research
FDA Clearance for PM647 Supports PRME’s Growth Prospects
A key positive development for Prime Medicine is the FDA's recent clearance of its investigational new drug application last month for PM647, an investigational gene-editing therapy for AATD. The clearance allows the company to advance PM647 into clinical testing in the United States.
PM647 is designed to correct the underlying genetic mutation responsible for AATD and restore the production of functional alpha-1 antitrypsin protein. The disease can cause progressive lung damage and liver disease. PM647 aims to address its genetic cause through a single treatment.
The planned phase I/II study will initially evaluate the therapy in adults with lung-related manifestations of AATD. The company may later enroll patients with significant liver disease after establishing the therapy's tolerability in the initial group. If clinical trials demonstrate acceptable safety and meaningful benefits, PM647 could emerge as a potential new treatment option for patients with this genetic disorder.
PRME’s PM577a Enters Clinical Testing for Wilson Disease
Another positive development is the dosing of the first patient in the global phase I/II clinical study of PM577a for Wilson disease in October. This milestone marks an important step in Prime Medicine's efforts to advance its in vivo Prime Editing approach into human clinical trials.
PM577a is designed to correct the H1069Q mutation in the ATP7B gene, which is a common cause of Wilson disease in North America and Europe. The genetic disorder causes copper to accumulate in the body, potentially damaging the liver, brain and other organs. Current drug treatments require lifelong management, while liver transplantation remains the only established curative option.
The study will assess the safety, tolerability and preliminary effectiveness of PM577a in adults and adolescents with the targeted mutation. If successful, the treatment could offer a one-time approach that addresses the underlying genetic cause of the disease. The initial data readout is expected in 2027.
The FDA granted Rare Pediatric Disease designation to PM577 for Wilson disease, recognizing the need for treatments for serious or life-threatening diseases affecting children.
However, both candidates remain investigational, and their ultimate value will depend on clinical safety, efficacy and future regulatory outcomes.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have surged 248.2% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met on the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 41.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Key Takeaways
Prime Medicine (PRME - Free Report) shares have gained approximately 26% over the past month against the industry’s 2.8% decline, supported by encouraging clinical and regulatory progress across its gene-editing pipeline. Prime Medicine received FDA clearance for its investigational therapy PM647 for alpha-1 antitrypsin deficiency (AATD). The company also announced the dosing of the first patient in the phase I/II study of investigational PM577a for Wilson disease. These milestones highlight the potential of the company's Prime Editing platform to develop treatments that target the underlying causes of genetic diseases.
Image Source: Zacks Investment Research
FDA Clearance for PM647 Supports PRME’s Growth Prospects
A key positive development for Prime Medicine is the FDA's recent clearance of its investigational new drug application last month for PM647, an investigational gene-editing therapy for AATD. The clearance allows the company to advance PM647 into clinical testing in the United States.
PM647 is designed to correct the underlying genetic mutation responsible for AATD and restore the production of functional alpha-1 antitrypsin protein. The disease can cause progressive lung damage and liver disease. PM647 aims to address its genetic cause through a single treatment.
The planned phase I/II study will initially evaluate the therapy in adults with lung-related manifestations of AATD. The company may later enroll patients with significant liver disease after establishing the therapy's tolerability in the initial group. If clinical trials demonstrate acceptable safety and meaningful benefits, PM647 could emerge as a potential new treatment option for patients with this genetic disorder.
PRME’s PM577a Enters Clinical Testing for Wilson Disease
Another positive development is the dosing of the first patient in the global phase I/II clinical study of PM577a for Wilson disease in October. This milestone marks an important step in Prime Medicine's efforts to advance its in vivo Prime Editing approach into human clinical trials.
PM577a is designed to correct the H1069Q mutation in the ATP7B gene, which is a common cause of Wilson disease in North America and Europe. The genetic disorder causes copper to accumulate in the body, potentially damaging the liver, brain and other organs. Current drug treatments require lifelong management, while liver transplantation remains the only established curative option.
The study will assess the safety, tolerability and preliminary effectiveness of PM577a in adults and adolescents with the targeted mutation. If successful, the treatment could offer a one-time approach that addresses the underlying genetic cause of the disease. The initial data readout is expected in 2027.
The FDA granted Rare Pediatric Disease designation to PM577 for Wilson disease, recognizing the need for treatments for serious or life-threatening diseases affecting children.
However, both candidates remain investigational, and their ultimate value will depend on clinical safety, efficacy and future regulatory outcomes.
Prime Medicine, Inc. Price and Consensus
Prime Medicine, Inc. price-consensus-chart | Prime Medicine, Inc. Quote
PRME's Zacks Rank & Stocks to Consider
Prime Medicine currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Corcept Therapeutics (CORT - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have surged 248.2% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met on the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 41.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.